



**Aarti Drugs Limited**

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

**Ref: ADL/SE/2020-21**

**May 18, 2020**

To,  
Listing/ Compliance Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
BSE ID: AARTIDRUGS  
**BSE CODE – 524348**

To,  
Listing/ Compliance Department  
**National Stock Exchange of India  
Limited,**  
“Exchange Plaza”, Bandra - Kurla  
Complex, Bandra (E), Mumbai – 400051  
**NSE SYMBOL: AARTIDRUGS**

Dear Sir/Madam,

**Sub: Press Release for March 2020**

Please find attached herewith press release on the financial results for the quarter and year ended March 31, 2020.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**FOR AARTI DRUGS LIMITED**

RUSHIKESH DEOLE

**COMPANY SECRETARY & COMPLIANCE OFFICER**

ICSI M.No.: A54527



**Aarti Drugs Limited**

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)  
Fax. : 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

### **Press release for March'2020**

In the March'2020 quarter, the Company recorded consolidated quarterly revenue of Rs.449.64 Crores with year-on-year decrease of 2.07%. This was due to unavailability of transportation and other services which temporarily affected the sales towards the end of March'20 month. API segment contributed approximately 89% and formulation around 11% of the total consolidated revenues. Domestic sales of the API segment grew by approximately 1.31% and exports were down by 14.93% due to COVID19 lockdown. Formulation segment revenues grew by around 26.52% on a year-on-year basis.

Consolidated EBITDA for the quarter ended March'2020 is Rs.80.68 Crores, up by 32.47% and consolidated profit after tax for the quarter ended March'2020 is Rs.58.86 Crores, up by 114.48% on a year-on-year basis. Consolidated EBITDA margin improved to 16.08% even after removing exceptional items of land sale. Company has improved on its gross margins on the account of better realizations and operational efficiency. Due to continuous improvement in working capital management, the Company was able to further reduce its Debt/Equity ratio to 0.58 as of March'2020 on a consolidated basis.

Company has already scaled up its anti-diabetic and anti-inflammatory capacity and it will give impetus to revenue growth in FY20-21. Further CAPEX is planned for introducing new products in anti-diabetic category. Due to lockdown a lot of services are scarce and hence it is affecting productivity to some extent. However, due to the essential nature of our business, we are running our factories after practicing appropriate social distancing measures, regular health check-ups, enhanced insurance, etc.

**FOR AARTI DRUGS LIMITED**

**ADHISH P. PATIL**  
**CHIEF FINANCIAL OFFICER**